Art. -Nr.: HY-N4309A

Lotusine hydroxide

Kundenbewertung

Based on 1 Customer Validation

Lotusine hydroxide is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against α-amylase and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine hydroxide inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine hydroxide induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine hydroxide reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine hydroxide is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.56%
CAS. Nr.: 3721-76-4
Formel: C₁₉H₂₅NO₄
Molecular Weight:331.41

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Lotusine hydroxide Chemical Structure

CAS. Nr.: 3721-76-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Lotusine hydroxide (2, 4, 10 μM; 24, 48, 72 h) potently inhibits proliferation of EGFR-mutant HCC827 NSCLC cells and EGFR-wildtype A549 NSCLC cells in time- and concentration-dependent manners, with stronger activity against HCC827 cells (73% inhibition at 10 μM for 72 h)^[1].
Lotusine hydroxide (2.5, 5, 10 μM; 24 h) induces concentration-dependent apoptosis in EGFR-mutant HCC827 NSCLC cells, with 80% of cells undergoing apoptosis at 10 μM for 24 h^[1].
Lotusine hydroxide (2.5, 5, 10 μM; 24 h) disrupts mitochondrial membrane potential in EGFR-mutant HCC827 NSCLC cells in a concentration-dependent manner, as evidenced by reduced JC-1 fluorescence ratios at 2.5, 5, and 10 μM for 24 h^[1].
Lotusine hydroxide (2.5, 5, 10 μM; 72 h) induces concentration-dependent G0/G1 phase cell cycle arrest in EGFR-mutant HCC827 NSCLC cells, halting progression into the DNA synthesis phase^[1].
Lotusine hydroxide (2.5, 5, 10 μM; 24 h) inhibits the EGFR-Akt-ERK signaling pathway in EGFR-mutant HCC827 NSCLC cells in vitro in a concentration-dependent manner, reducing p-EGFR, p-Akt, and p-ERK levels most significantly at 10 μM for 24 h^[1].
Lotusine hydroxide (25-50 μM; 48-72 h) does not significantly reduce the viability of HepG2 cells when administered alone or in combination with 25 mM D-glucose, maintaining 85-90% cell viability^[2].
Lotusine hydroxide (25-50 μM; 48-72 h, co-treated with 25 mM D-glucose) reverses hyperglycemia-induced reductions in SOD, CAT, and GPx antioxidant enzyme activities and lowers elevated MDA levels in HepG2 cells^[2].
Lotusine hydroxide (1.56-200 μg/mL; 10 min) inhibits alpha-amylase activity with an IC₅₀ of 30.60 μg/mL, and achieves 80.36% inhibition at a concentration of 200 μg/mL in a cell-free biochemical assay^[2].
Lotusine hydroxide (1.56-200 μg/mL; 20 min) inhibits alpha-glucosidase activity with an IC₅₀ of 36.15 μg/mL, and achieves 82.6% inhibition at a concentration of 200 μg/mL in a cell-free biochemical assay^[2].
Lotusine hydroxide (10-1000 μM; 24 h) exhibits low cytotoxicity in H9c2 cells, with an IC₅₀ of 701 μM, and concentrations of 10, 50, and 100 μM maintain cell viability near control levels^[3].
Lotusine hydroxide (10-100 μM) enhances endogenous antioxidant (SOD, CAT, GSH) levels in H9c2 cells exposed to doxorubicin, supporting protection against oxidative stress^[3].
Lotusine hydroxide (10-100 μM) significantly reduces doxorubicin-induced lipid peroxidation in H9c2 cells, with 50 μM showing the greatest reduction^[3].
Lotusine hydroxide (10-50 μM; 24 h pretreatment) prevents doxorubicin-induced morphological and nuclear abnormalities in H9c2 cells^[3].
Lotusine hydroxide (10-50 μM) completely inhibits doxorubicin-induced ROS generation in H9c2 cells^[3].
Lotusine hydroxide (10-50 μM) modulates apoptotic gene expression in H9c2 cells exposed to doxorubicin, upregulating Bcl-2 and downregulating Bax and Cas-3 to inhibit apoptosis^[3].
Lotusine hydroxide (10-50 μM; 24 h pretreatment) reduces doxorubicin-induced caspase-3/7 activity in H9c2 cells, with 50 μM showing activity comparable to control cells^[3].
Lotusine hydroxide (50 μM; 3 h) directly interacts with and stabilizes DRD1 protein in PC12 cells^[4].
Lotusine hydroxide (3.12-25 μM; 48 h following 1 h 38 mM PPA pretreatment) protects PC12 cells against PPA-induced cytotoxicity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

human EGFR-mutant HCC827 NSCLC cells, human EGFR-wildtype A549 NSCLC cells
Concentration:

2.5, 5, 10 μM
Incubation Time:

24 h, 48 h, 72 h
Result:

Inhibited approximately 73% of HCC827 cell proliferation at 10 μM for 72 h.
Inhibited approximately 52% of A549 cell proliferation at 10 μM for 72 h.
Exhibited time- and concentration-dependent inhibitory effects on both cell lines, with more pronounced activity in HCC827 cells.

Apoptosis Analysis^[1]

Cell Line:

human EGFR-mutant HCC827 NSCLC cells
Concentration:

2.5 μM (24 h); 5 μM (24 h); 10 μM (24 h)
Incubation Time:

24 h (2.5 μM); 24 h (5 μM); 24 h (10 μM)
Result:

Induced a substantial increase in apoptosis relative to untreated cells at 2.5 μM for 24 h.
Induced apoptosis in more than 50% of HCC827 cells at 5 μM for 24 h.
Induced apoptosis in approximately 80% of HCC827 cells at 10 μM for 24 h.

Cell Cycle Analysis^[1]

Cell Line:

human EGFR-mutant HCC827 NSCLC cells
Concentration:

2.5 μM (72 h); 5 μM (72 h); 10 μM (72 h)
Incubation Time:

72 h (2.5 μM); 72 h (5 μM); 72 h (10 μM)
Result:

Increased the proportion of cells in the G0/G1 phase in a concentration-dependent manner.
Decreased the S and G2/M phase cell populations in a concentration-dependent manner.

Western Blot Analysis^[1]

Cell Line:

human EGFR-mutant HCC827 NSCLC cells
Concentration:

2.5 μM (24 h); 5 μM (24 h); 10 μM (24 h)
Incubation Time:

24 h (2.5 μM); 24 h (5 μM); 24 h (10 μM)
Result:

Reduced phosphorylated EGFR (p-EGFR) levels in a concentration-dependent manner.
Reduced phosphorylated Akt (p-Akt) levels in a concentration-dependent manner.
Reduced phosphorylated ERK (p-ERK) levels in a concentration-dependent manner.
Showed the highest inhibitory activity at 10 μM for 24 h.

Cell Viability Assay^[2]

Cell Line:

HepG2 cells
Concentration:

25 μM (alone; combined with 25 mM D-glucose); 50 μM (alone; combined with 25 mM D-glucose)
Incubation Time:

48 h (25 μM alone; 25 μM + 25 mM D-glucose); 72 h (50 μM alone; 50 μM + 25 mM D-glucose)
Result:

Maintained 85-90% of HepG2 cell viability.
Showed no significant reduction in viability relative to control cells.

Cell Cytotoxicity Assay^[3]

Cell Line:

H9c2
Concentration:

10, 50, 100, 250, 500, 1000 μM
Incubation Time:

24 h
Result:

Exhibited an IC₅₀ value of 701 μM.
Maintained cell viability near control levels at 10, 50, and 100 μM.
Caused significant decreases in cell viability at concentrations from 250 to 1000 μM.

Cell Viability Assay^[3]

Cell Line:

H9c2
Concentration:

10, 50, 100 μM (pretreated prior to doxorubicin exposure)
Incubation Time:

24 h (pretreatment); 24 h (doxorubicin exposure)
Result:

Maintained cell viability near control levels at 10 μM.
Induced cell proliferation at 50 μM, with viability values of 118.53 % (SRB assay) and 110.36 % (MTT assay).
Caused significantly reduced cell viability at 100 μM (84.41% in SRB assay, 79.84 % in MTT assay).

Western Blot Analysis^[4]

Cell Line:

rat pheochromocytoma PC12 cells
Concentration:

6.25 μM
Incubation Time:

48 h (following 1 h 38 mM PPA pretreatment)
Result:

Restored PPA-induced reductions in DRD1, c-fos, GluA1, p-GluA1 Ser 845, and p-GluA1 Ser 831 protein levels.
Had its rescue effect abolished when co-treated with the DRD1 antagonist SCH23390.

In Vivo

Lotusine hydroxide (50 mg/kg bw; diet supplementation; daily; 4 weeks) restores antioxidant vitamin levels and liver protein content, improves growth performance, and normalizes relative organ weight in streptozotocin-induced diabetic rats^[2].
Lotusine hydroxide (5-20 mg/kg; p.o.; daily; 5 days) ameliorates propionic acid-induced ASD-like social deficits and cognitive impairments in mice, with 10 and 20 mg/kg doses also restoring mPFC neuronal activity and AMPA receptor function via upregulation of c-fos and phosphorylated GluA1 levels^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar (Sprague Dawley) (male, 160 ± 20 g, streptozotocin-induced diabetes mellitus)^[2]
Dosage:

50 mg/kg bw
Administration:

diet supplementation; daily; 4 weeks
Result:

Restored serum, liver, and pancreatic vitamin C and E concentrations to near-normal values (liver vitamin C: 160 mg/100g; liver vitamin E: 2990 mg/100g).
Increased liver cell protein content to 11.6 mg/g.
Enhanced body weight gain by 45% compared to untreated diabetic rats (final body weight: 225.5 g; body weight gain: 65.3 g).
Reduced feed conversion ratio to 1.45, matching the ratio of non-diabetic control rats.
Lowered relative organ weight to 2.49%, a level comparable to non-diabetic control rats.
Maintained 100% survival rate.

Animal Model:

C57BL/6J (male, 6-8 weeks old, 20 ± 2 g, intracerebroventricular injection of propionic acid to induce ASD-like behavior)^[4]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

p.o.; daily; 5 days
Result:

Significantly increased interaction time with a stranger mouse in the sociability test and with a novel stranger mouse in the social novelty test reversing PPA-induced social deficits.
Significantly increased the percentage of spontaneous alternations in the Y-maze test.
Significantly reversed the PPA-induced reduction in miniature excitatory postsynaptic current frequency in the medial prefrontal cortex at 10 mg/kg, with no effect on amplitude.
Significantly increased c-fos protein levels in the mPFC, reversing PPA-induced reductions.
Reversed PPA-induced reductions in p-GluA1 Ser845 protein levels in the mPFC; reversed PPA-induced reductions in p-GluA1 Ser831 protein levels in the mPFC .

Chemical Information

CAS. Nr. 3721-76-4
Appearance Solid
Molecular Weight 331.41
Formel C₁₉H₂₅NO₄
Color White to off-white
SMILES

C[N+]1(C)[C@H](CC2=CC=C(O)C=C2)C3=C(C=C(O)C(OC)=C3)CC1.[OH-]
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (100.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0174 mL

15.0871 mL

30.1741 mL

5 mM

0.6035 mL

3.0174 mL

6.0348 mL

10 mM

0.3017 mL

1.5087 mL

3.0174 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lan Y, et al. Anti-lung cancer activity of lotusine in non-small cell lung cancer HCC827 via reducing proliferation, oxidative stress, induction of apoptosis, and G0/G1 cell cycle arrest via suppressing EGFR-Akt-ERK signalling. In Vitro Cell Dev Biol Anim. 2025;61(4):450-458. [Content Brief]

[2]. Nahed S. Alharthi, et al. Prophylactic Impacts of Lotusine Against Hyperglycaemia-Induced Oxidative Stress in Hepatic Cells Isolated from Diabetic Rats Via Irs-1/Pi3 K/Akt Pathway. Pak Vet J, 45(1): 124-137.

[3]. Harishkumar R, et al. Lotusine, an alkaloid from Nelumbo nucifera (Gaertn.), attenuates doxorubicin-induced toxicity in embryonically derived H9c2 cells. In Vitro Cell Dev Biol Anim. 2020;56(5):367-377. [Content Brief]

[4]. Liu QQ, et al. Lotusine ameliorates propionic acid-induced autism spectrum disorder-like behavior in mice by activating D1 dopamine receptor in medial prefrontal cortex. Phytother Res. 2024;38(2):1089-1103. [Content Brief]

[5]. Le Crouéour G, et al. Lotusine G: a new cyclopeptide alkaloid from Zizyphus lotus. Fitoterapia. 2002;73(1):63-68. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0174 mL	15.0871 mL	30.1741 mL	75.4353 mL
	5 mM	0.6035 mL	3.0174 mL	6.0348 mL	15.0871 mL
	10 mM	0.3017 mL	1.5087 mL	3.0174 mL	7.5435 mL
	15 mM	0.2012 mL	1.0058 mL	2.0116 mL	5.0290 mL
	20 mM	0.1509 mL	0.7544 mL	1.5087 mL	3.7718 mL
	25 mM	0.1207 mL	0.6035 mL	1.2070 mL	3.0174 mL
	30 mM	0.1006 mL	0.5029 mL	1.0058 mL	2.5145 mL
	40 mM	0.0754 mL	0.3772 mL	0.7544 mL	1.8859 mL
	50 mM	0.0603 mL	0.3017 mL	0.6035 mL	1.5087 mL
	60 mM	0.0503 mL	0.2515 mL	0.5029 mL	1.2573 mL
	80 mM	0.0377 mL	0.1886 mL	0.3772 mL	0.9429 mL
	100 mM	0.0302 mL	0.1509 mL	0.3017 mL	0.7544 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Lotusine hydroxide

Metabolism/Protease Compound Library

Natural Product Library

Anti-Aging Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Alkaloids Library

Anti-Lung Cancer Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Lotusine hydroxide

Metabolism/Protease Compound Library

Natural Product Library

Anti-Aging Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Alkaloids Library

Anti-Lung Cancer Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Lotusine hydroxide Related Classifications

HY-N4309A Related Classifications